Chemed
Stock Forecast, Prediction & Price Target
Chemed Financial Estimates
Chemed Revenue Estimates
Chemed EBITDA Estimates
Chemed Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | ||
Revenue
% change YoY
| $2.13B N/A | $2.13B -0.20% | $2.26B 6.06% | Avg: $2.59B Low: $2.57B High: $2.60B avg. 14.56% | Avg: $2.76B Low: $2.73B High: $2.77B avg. 6.51% | ||
Net Income
% change YoY
| $268.55M N/A | $249.62M -7.04% | $272.50M 9.16% | Avg: $356.07M Low: $341.39M High: $368.75M avg. 30.66% | Avg: $404.47M Low: $399.89M High: $407.64M avg. 13.59% | ||
EBITDA
% change YoY
| $411.23M N/A | $393.43M -4.32% | $414.34M 5.31% | Avg: $484.68M Low: $480.46M High: $487.61M avg. 16.97% | Avg: $516.27M Low: $511.77M High: $519.39M avg. 6.51% | ||
EPS
% change YoY
| $17.14 N/A | $16.72 -2.45% | $18.11 8.31% | Avg: $23.36 Low: $22.46 High: $24.26 avg. 28.98% | Avg: $26.61 Low: $26.31 High: $26.82 avg. 13.91% | ||
Operating Expenses
% change YoY
| $426.76M N/A | $421.59M -1.21% | $455.98M 8.15% | Avg: $430.86M Low: $427.11M High: $433.46M avg. -5.50% | Avg: $458.94M Low: $454.94M High: $461.72M avg. 6.51% | ||
FAQ
What is Chemed stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 22.12% in 2025-2026.
We have gathered data from 2 analysts. Their low estimate is 341.39M, average is 356.07M and high is 368.75M.
What is Chemed stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 10.54% in 2025-2026.
We have gathered data from 2 analysts. Their low revenue estimate is $2.57B, average is $2.59B and high is $2.60B.
What is Chemed stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 21.45% in 2025-2026.
We have gathered data from 2 analysts. Their low earnings per share estimate is $22.46, average is $23.36 and high is $24.26.
What is the best performing analyst?
In the last twelve months analysts have been covering Chemed stock. The most successful analyst is Frank Morgan.